AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
mirdametinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| MEK (MAPK kinase) tyrosine kinase inhibitors | 5808 | 1013101-36-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Mirdametinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). MEK1/2 proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 2, 2025 | FDA | SpringWorks Therapeutics | |
| July 17, 2025 | EMA | Merck Europe B.V. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01EE05 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Mitogen-activated protein kinase (MEK) inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D047428 | Protein Kinase Inhibitors |
| FDA EPC | N0000175605 | Kinase Inhibitor |
| FDA MoA | N0000193943 | Mitogen-Activated Protein Kinase Kinase 1 Inhibitors |
| FDA MoA | N0000193944 | Mitogen-Activated Protein Kinase Kinase 2 Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:88286 | EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor |
Related Drugs by ATC class:
L01EE Mitogen-activated protein kinase (MEK) inhibitors 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Neurofibromatosis type 1 | indication | 92824003 | DOID:0111253 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 11453641 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 11806321 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 11819487 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12011424 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12037306 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12090128 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12263146 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12295925 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12357597 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11453641 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11806321 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11819487 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12011424 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12037306 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12263146 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12275688 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12295925 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11453641 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11806321 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11819487 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12037306 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12263146 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12275688 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12295925 | Feb. 17, 2041 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 11839595 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 11883375 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12220390 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12257215 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12324791 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11839595 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11883375 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12220390 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12257215 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12324791 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11839595 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11883375 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12220390 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12257215 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12324791 | March 16, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 11806322 | April 9, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11806322 | April 9, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 11806322 | April 9, 2043 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12661330 | Feb. 5, 2044 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12661330 | Feb. 5, 2044 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12661330 | Feb. 5, 2044 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12029711 | March 15, 2044 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12029711 | March 15, 2044 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12383517 | March 15, 2044 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12029711 | March 15, 2044 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12383517 | March 15, 2044 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | 12390430 | Oct. 10, 2044 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12390430 | Oct. 10, 2044 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | 12390430 | Oct. 10, 2044 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | Feb. 11, 2030 | NEW CHEMICAL ENTITY |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | Feb. 11, 2030 | NEW CHEMICAL ENTITY |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | Feb. 11, 2030 | NEW CHEMICAL ENTITY |
| 1MG | GOMEKLI | SPRINGWORKS | N219379 | Feb. 11, 2025 | RX | TABLET, FOR SUSPENSION | ORAL | Feb. 11, 2032 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 1MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | Feb. 11, 2032 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
| 2MG | GOMEKLI | SPRINGWORKS | N219389 | Feb. 11, 2025 | RX | CAPSULE | ORAL | Feb. 11, 2032 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Dual specificity mitogen-activated protein kinase kinase 1 | Kinase | INHIBITOR | Ki | 8.96 | DRUG LABEL | DRUG LABEL | |||
| Dual specificity mitogen-activated protein kinase kinase 2 | Kinase | INHIBITOR | Ki | 9.10 | DRUG LABEL | DRUG LABEL | |||
| Serine/threonine-protein kinase B-raf | Kinase | IC50 | 8.22 | CHEMBL | |||||
| Mitogen-activated protein kinase 1 | Kinase | IC50 | 7.60 | CHEMBL | |||||
| Dual specificity mitogen-activated protein kinase kinase 5 | Kinase | Kd | 6.09 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 391210-10-9 | SECONDARY_CAS_RN |
| CHEMBL507361 | ChEMBL_ID |
| C506614 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB07101 | DRUGBANK_ID |
| 4043753 | VANDF |
| C5447979 | UMLSCUI |
| 4BM | PDB_CHEM_ID |
| 11299 | INN_ID |
| 9826528 | PUBCHEM_CID |
| 392768 | MMSL |
| 43745 | MMSL |
| d10257 | MMSL |
| 020002 | NDDF |
| 7935 | IUPHAR_LIGAND_ID |
| 86K0J5AK6M | UNII |
| 2705551 | RXNORM |
| D11675 | KEGG_DRUG |
| CHEBI:88249 | CHEBI |
| 86K0J5AK6M | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Gomekli | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82448-130 | CAPSULE | 1 mg | ORAL | NDA | 28 sections |
| Gomekli | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82448-130 | CAPSULE | 1 mg | ORAL | NDA | 28 sections |
| Gomekli | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82448-134 | TABLET, FOR SUSPENSION | 1 mg | ORAL | NDA | 28 sections |
| Gomekli | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82448-134 | TABLET, FOR SUSPENSION | 1 mg | ORAL | NDA | 28 sections |
| Gomekli | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82448-260 | CAPSULE | 2 mg | ORAL | NDA | 28 sections |
| Gomekli | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82448-260 | CAPSULE | 2 mg | ORAL | NDA | 28 sections |